453 related articles for article (PubMed ID: 30504367)
1. Targeted Therapies for Pancreatic Cancer and Hurdles Ahead.
Aslan M; Shahbazi R; Ulubayram K; Ozpolat B
Anticancer Res; 2018 Dec; 38(12):6591-6606. PubMed ID: 30504367
[TBL] [Abstract][Full Text] [Related]
2. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
[TBL] [Abstract][Full Text] [Related]
3. Mutations in key driver genes of pancreatic cancer: molecularly targeted therapies and other clinical implications.
Hu HF; Ye Z; Qin Y; Xu XW; Yu XJ; Zhuo QF; Ji SR
Acta Pharmacol Sin; 2021 Nov; 42(11):1725-1741. PubMed ID: 33574569
[TBL] [Abstract][Full Text] [Related]
4. Perspectives in the treatment of pancreatic adenocarcinoma.
Cid-Arregui A; Juarez V
World J Gastroenterol; 2015 Aug; 21(31):9297-316. PubMed ID: 26309356
[TBL] [Abstract][Full Text] [Related]
5. The critical roles of activated stellate cells-mediated paracrine signaling, metabolism and onco-immunology in pancreatic ductal adenocarcinoma.
Fu Y; Liu S; Zeng S; Shen H
Mol Cancer; 2018 Feb; 17(1):62. PubMed ID: 29458370
[TBL] [Abstract][Full Text] [Related]
6. Update on the management of pancreatic cancer: surgery is not enough.
Ansari D; Gustafsson A; Andersson R
World J Gastroenterol; 2015 Mar; 21(11):3157-65. PubMed ID: 25805920
[TBL] [Abstract][Full Text] [Related]
7. Pancreas cancer: Therapeutic trials in metastatic disease.
Smithy JW; O'Reilly EM
J Surg Oncol; 2021 May; 123(6):1475-1488. PubMed ID: 33831245
[TBL] [Abstract][Full Text] [Related]
8. The Emerging Role of Cyclin-Dependent Kinases (CDKs) in Pancreatic Ductal Adenocarcinoma.
GarcĂa-Reyes B; Kretz AL; Ruff JP; von Karstedt S; Hillenbrand A; Knippschild U; Henne-Bruns D; Lemke J
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30340359
[TBL] [Abstract][Full Text] [Related]
9. Stroma Involvement in Pancreatic Ductal Adenocarcinoma: An Overview Focusing on Extracellular Matrix Proteins.
Liot S; Balas J; Aubert A; Prigent L; Mercier-Gouy P; Verrier B; Bertolino P; Hennino A; Valcourt U; Lambert E
Front Immunol; 2021; 12():612271. PubMed ID: 33889150
[TBL] [Abstract][Full Text] [Related]
10. Pancreatic Cancer Stem Cells and Therapeutic Approaches.
Ercan G; Karlitepe A; Ozpolat B
Anticancer Res; 2017 Jun; 37(6):2761-2775. PubMed ID: 28551612
[TBL] [Abstract][Full Text] [Related]
11. Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies.
Adamska A; Domenichini A; Falasca M
Int J Mol Sci; 2017 Jun; 18(7):. PubMed ID: 28640192
[TBL] [Abstract][Full Text] [Related]
12. Biomarker-driven and molecularly targeted therapies for pancreatic adenocarcinoma.
Zhen DB; Coveler A; Zanon S; Reni M; Chiorean EG
Semin Oncol; 2018 Jun; 45(3):107-115. PubMed ID: 30391013
[TBL] [Abstract][Full Text] [Related]
13. Genetic progression of pancreatic cancer.
Cowan RW; Maitra A
Cancer J; 2014; 20(1):80-4. PubMed ID: 24445769
[TBL] [Abstract][Full Text] [Related]
14. Emerging Treatment Strategies in Pancreatic Cancer.
Trunk A; Miotke L; Nevala-Plagemann C; Verdaguer H; Macarulla T; Garrido-Laguna I
Pancreas; 2021 Jul; 50(6):773-787. PubMed ID: 34398070
[TBL] [Abstract][Full Text] [Related]
15. The evolution into personalized therapies in pancreatic ductal adenocarcinoma: challenges and opportunities.
Tesfaye AA; Kamgar M; Azmi A; Philip PA
Expert Rev Anticancer Ther; 2018 Feb; 18(2):131-148. PubMed ID: 29254387
[TBL] [Abstract][Full Text] [Related]
16. Challenges and future directions in therapeutics for pancreatic ductal adenocarcinoma.
Al Haddad AH; Adrian TE
Expert Opin Investig Drugs; 2014 Nov; 23(11):1499-515. PubMed ID: 25078674
[TBL] [Abstract][Full Text] [Related]
17. MYC in pancreatic cancer: novel mechanistic insights and their translation into therapeutic strategies.
Hessmann E; Schneider G; Ellenrieder V; Siveke JT
Oncogene; 2016 Mar; 35(13):1609-18. PubMed ID: 26119937
[TBL] [Abstract][Full Text] [Related]
18. Opportunities for translation: targeting DNA repair pathways in pancreatic cancer.
Maginn EN; de Sousa CH; Wasan HS; Stronach EA
Biochim Biophys Acta; 2014 Aug; 1846(1):45-54. PubMed ID: 24727386
[TBL] [Abstract][Full Text] [Related]
19. Targeting galectin-1 inhibits pancreatic cancer progression by modulating tumor-stroma crosstalk.
Orozco CA; Martinez-Bosch N; Guerrero PE; Vinaixa J; Dalotto-Moreno T; Iglesias M; Moreno M; Djurec M; Poirier F; Gabius HJ; Fernandez-Zapico ME; Hwang RF; Guerra C; Rabinovich GA; Navarro P
Proc Natl Acad Sci U S A; 2018 Apr; 115(16):E3769-E3778. PubMed ID: 29615514
[TBL] [Abstract][Full Text] [Related]
20. Biomarker-Based Therapy in Pancreatic Ductal Adenocarcinoma: An Emerging Reality?
Krantz BA; O'Reilly EM
Clin Cancer Res; 2018 May; 24(10):2241-2250. PubMed ID: 29269376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]